Trial · NCT00860067
Trial comparisons21
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 21
Download this page as JSON| Comparison | Source |
|---|---|
| Q/LAIV (MEDI3250) vs FluMist/B/Victoria: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Victoria Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 180 Days Post Vaccination | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Victoria: The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Victoria Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Victoria: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience B/Victoria Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Victoria: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a B/Victoria Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting New Onset Chronic Diseases From Administration of Investigational Product Through 180 Days Post Vaccination | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Seropositive Participants Within Each Treatment Arm Who Experience A/H3N2 Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H3N2 Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Participants Reporting Any Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H3N2 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a A/H3N2 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination | Trial comparisons |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Seropositive Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose. | Trial comparisons |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00860067/comparisons